ライフサイエンスコーパス: plasma insulin

1 Exendin-4 microinjections increased plasma insulin.

2 protein folding and islet apoptosis to lower plasma insulin.

3 d hyperglycemia, smaller islets, and reduced plasma insulin.

4 oordinated to yield coherent oscillations in plasma insulin.

5 nd enhanced glucose tolerance with decreased plasma insulin.

6 ether this is associated with an increase in plasma insulin.

7 free fatty acids, and glucose but increased plasma insulin.

8 izes plasma glucose and significantly lowers plasma insulin.

9 ependent of other adipose depots and fasting plasma insulin.

10 ependent of other adipose depots and fasting plasma insulin.

11 are interacting with an internal signal, the plasma insulin.

12 cated by an approximately 2-fold increase in plasma insulin.

13 glucose levels but had no effect on fasting plasma insulin.

14 nsulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibito

15 ment with pioglitazone significantly lowered plasma insulin (-22.9%; P<0.001), improved QUICKI insuli

16 Plasma insulin (599 +/- 28 pmol/l) and glucose (2.9 +/-

17 were accompanied by significant decreases in plasma insulin (62%) and leptin (41%).

18 2.37) after adjusting for age, sex, fasting plasma insulin, a nonlinear transformation of 2-hour pla

19 ologies used to evoke sustained increases in plasma insulin: a mixed meal and a hyperinsulinaemic eug

20 areas under the curve for blood glucose and plasma insulin after oral glucose, lower plasma adiponec

21 Arterial plasma insulin also fell to similar minima in both group

22 ell-established inverse relationship between plasma insulin and adiponectin levels may, in part, refl

23 paired glucose tolerance, B6 mice have lower plasma insulin and are more insulin sensitive than AKR m

24 Leucine-10g, but not leucine-5g, increased plasma insulin and C-peptide AUCs (P < 0.01 for both), b

25 lucose tolerance tests were used to generate plasma insulin and C-peptide data in conscious dogs that

26 e report markedly reduced glucose-responsive plasma insulin and C-peptide levels in whole body Map4k4

27 p studies of Wistar rats, CGP37157 increased plasma insulin and C-peptide levels only during the hype

28 tic and extrahepatic insulin clearance using plasma insulin and C-peptide profiles obtained from the

29 lucose utilization increased with increasing plasma insulin and decreasing FFA levels.

30 Increases in plasma insulin and exercise/muscle contraction lead to r

31 Fasting plasma insulin and free fatty acid levels were lower in

32 effects could be dissociated from changes in plasma insulin and glucagon concentrations and hepatic g

33 Matching plasma insulin and glucagon with portal infusions led to

34 f which was additionally associated with 2-h plasma insulin and glucose as well as insulin action at

35 Plasma insulin and glucose concentrations are important

36 y, which was reflected by a lowering of both plasma insulin and glucose levels and improved glucose a

37 Plasma insulin and glucose levels in vivo were assessed

38 The relative importance of plasma insulin and glucose levels on the abnormal vasodi

39 Fasting plasma insulin and glucose levels were measured, and glu

40 hepatomegaly and steatosis, and postprandial plasma insulin and glucose levels.

41 in secretion of GLP-1 and the regulation of plasma insulin and glucose.

42 scle GLUT4 protein and improved both fasting plasma insulin and hepatic triacylglyceride levels, but

43 so showed association with decreased fasting plasma insulin and homeostatic model assessment of insul

44 ould be predicted by the combination of high plasma insulin and inflammatory markers before dietary i

45 , with no differences between diets, fasting plasma insulin and insulin resistance were lower after t

46 Both plasma insulin and leptin act in the central nervous sys

47 Decreases in plasma insulin and leptin concentrations between 14 and

48 biological responses to acute elevations in plasma insulin and leptin concentrations.

49 ncreatic beta cell hyperplasia, and elevated plasma insulin and leptin concentrations.

50 te hormone levels with early (6 hr) rises in plasma insulin and leptin followed by persisting subnorm

51 f plasma ketone bodies but reduced levels of plasma insulin and leptin.

52 rats had no predictable relationship between plasma insulin and leptin.

53 Plasma insulin and pancreatic polypeptide concentrations

54 acid metabolism still responds to changes in plasma insulin and plasma FFA levels.

55 (bethanechol) led to significantly increased plasma insulin and reduced blood glucose levels, as comp

56 Pyruvate challenge stimulated increased plasma insulin and smaller excursions in blood glucose i

57 ucose or plasma free fatty acids, but fasted plasma insulin and the homeostatic model assessment of i

58 ith tesaglitazar was associated with reduced plasma insulin and total triglyceride levels and increas

59 slightly reduced blood glucose and increased plasma insulin, and decreased antral pressures (all P <

60 ntly lower waist-to-hip ratio (WHR), fasting plasma insulin, and fasting triglycerides.

61 with increases in percent body fat, fasting plasma insulin, and HGO (r = 0.34, 0.36, and 0.37; all P

62 rrelated with BMI and fat mass, body weight, plasma insulin, and homeostasis model assessment of insu

63 panied by increased blood glucose, decreased plasma insulin, and impaired glucose tolerance.

64 ce had significantly reduced total body fat, plasma insulin, and increased brown adipose tissue UCP1

65 Body weight, fasting plasma glucose, plasma insulin, and intraperitoneal glucose tolerance te

66 nt main effects to increases in body weight, plasma insulin, and plasma glucose.

67 anine brain senses physiologic elevations in plasma insulin, and that this in turn regulates genetic

68 mice) results in hypoglycemia with decreased plasma insulin, and the p85alpha(+/-) mice exhibit signi

69 Hyperinsulinemia (HI) is elevated plasma insulin at basal glucose.

70 hyperinsulinaemia, but other factors reduce plasma insulin at euglycaemia.

71 We conclude that plasma insulin AUC for the arterial insulin level (muscl

72 Furthermore, plasma insulin but not glucose levels together with home

73 ither A3GALT2 or NRG4, with markedly reduced plasma insulin C-peptide concentrations; and at SLC9A3R1

74 13)C-acetate breath test) and blood glucose, plasma insulin, C-peptide, glucagon, glucagon-like pepti

75 ates testes and restores fertility, but this plasma insulin cannot pass through the blood-testis barr

76 ), waist circumference (0.32 cm, 0.16-0.47), plasma insulin concentration (1.62%, 0.53-2.72), and pla

77 sized that modest, physiologic increments in plasma insulin concentration alter microvascular perfusi

78 dians with normal glucose tolerance, fasting plasma insulin concentration and insulin-stimulated gluc

79 Mean steady-state plasma insulin concentration during the GSIS study was r

80 conclusion, modest physiologic increments in plasma insulin concentration increased microvascular blo

81 Pancreatic insulin content and plasma insulin concentration of Lean-huIAPP transgenic m

82 (5.1 +/- 3.9 years), a high relative fasting plasma insulin concentration predicted a decline in AIR

83 The adjusted fasting plasma insulin concentration was a familial trait (herit

84 ively over 6.4 +/- 3.9 years, a high fasting plasma insulin concentration was a significant independe

85 The plasma insulin concentration was also lower in the GK tr

86 tissue was inversely related to BMI, fasting plasma insulin concentration, and the homeostasis model

87 With both protocols, muscle glucose uptake, plasma insulin concentration, and total blood flow to th

88 as a function of glucose production rate and plasma insulin concentration, was inversely correlated w

89 did not change after adjustment for fasting plasma insulin concentration.

90 in parallel with the changes observed in the plasma insulin concentration.

91 response (beta = 0.78, P = 0.03) and 30-min plasma insulin concentrations (beta = 0.78, P = 1.1 x 10

92 0.91; P = 0.04) but had no effect on fasting plasma insulin concentrations (MD: -0.79 pmol/L; 95% CI:

93 ght-maintenance control diet) raised fasting plasma insulin concentrations (MD: 3.38 pmol/L; 95% CI:

94 patic insulin action (P = 0.03), and fasting plasma insulin concentrations (P = 0.01).

95 fat intake resulted in significantly higher plasma insulin concentrations (P = 0.013), a more rapid

96 glucose tolerance and trended toward higher plasma insulin concentrations after intraperitoneal gluc

97 az-null mice did, however, display increased plasma insulin concentrations and a corresponding increa

98 (-1) x g(-1), p = 0.0002) despite comparable plasma insulin concentrations and a higher blood glucose

99 id infusion rates, independent of changes in plasma insulin concentrations and independent of hepatoc

100 alcoholic beverages on blood alcohol levels, plasma insulin concentrations and plasma glucose concent

101 travenous glucose (AIRg) was calculated from plasma insulin concentrations between 2 and 10 min after

102 Insulin infusion raised plasma insulin concentrations by approximately 10-fold.

103 emia and glucose intolerance and had reduced plasma insulin concentrations compared with controls.

104 ated peripheral glucose uptake under matched plasma insulin concentrations during the clamp.

105 0.01), associated with significantly higher plasma insulin concentrations following the oral glucose

106 uced plasma glucose excursions and increased plasma insulin concentrations in a mouse model of diabet

107 Hypoglycaemia significantly decreased plasma insulin concentrations in H (0.13 +/- 0.01 ng ml(

108 ing plasma glucose and increased circulating plasma insulin concentrations in high fat-fed mice.

109 Jejunal feeding resulted in higher peak plasma insulin concentrations than did gastric feeding (

110 African Americans (AAs) tend to have higher plasma insulin concentrations than European Americans (E

111 glucose tolerance test was normal, but their plasma insulin concentrations were higher than those of

112 Plasma insulin concentrations were inappropriately eleva

113 Plasma insulin concentrations were not different at eugl

114 Under hypoxaemic conditions, euglycaemic plasma insulin concentrations were reduced (P < 0.05) in

115 Arterial blood glucose and plasma insulin concentrations were similar in WT, G4(+/-

116 HA, H454Y mice had fasting hypoglycemia, but plasma insulin concentrations were similar to the contro

117 is, appetite, and food reward, despite lower plasma insulin concentrations, but reduced glucose uptak

118 relatively small increases (15 to 70 pM) in plasma insulin concentrations.

119 lutamine significantly increased circulating plasma insulin concentrations.

120 c insulin action (P = 0.05), but not fasting plasma insulin concentrations.

121 ere associated with inappropriately elevated plasma insulin concentrations.

122 azone treatment was accounted for by lowered plasma insulin concentrations.

123 tentiates insulin sensitivity, and increases plasma insulin concentrations.

124 or both; post-glucose insulin area under the plasma insulin curve during the 120 min of the test adju

125 nd the hepatic portal-arterial difference in plasma insulin decreased (P < 0.01) from 78 +/- 18 and 9

126 Epicatechin supplementation improved fasting plasma insulin (Delta insulin: -1.46 mU/L; 95% CI: -2.74

127 blood sampled serially for blood glucose and plasma insulin determinations.

128 glucose concentrations and increased fasting plasma insulin during an oral glucose tolerance test (al

129 ratio 2.3 [95% CI 1.0-5.2]) and with 30-min plasma insulin during oral glucose tolerance test in 287

130 st time in healthy humans, that increases in plasma insulin enhance the gain of arterial baroreflex c

131 sure pancreatic exocrine secretion (PES) and plasma insulin following microinjection of metabotropic

132 roscopy; (2) fasting plasma glucose, fasting plasma insulin (FPI), and free fatty acid (FFA) levels;

133 o 6.4 +/- 0.2 mmol/l at 30 min) and arterial plasma insulin (from 48 +/- 6 to 126 +/- 30 pmol/l at 30

134 However, choline deficiency lowered fasting plasma insulin (from 983 +/- 175 to 433 +/- 36 pmol/l, P

135 tide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared wit

136 Fasting plasma insulin, glucose, and free fatty acid (FFA) level

137 disease risk markers, including postprandial plasma insulin, glucose, and oxidative stress.

138 The plasma insulin/glucose ratio was ordered RLIP76(-/-) < R

139 was defined as blood glucose < 50 mg/dL AND plasma insulin > 3 mU/L at 120 minutes post glucose chal

140 L, n = 18) or hyperinsulinemic (HI) (fasting plasma insulin >11.2 mU/L, n = 19).

141 significantly higher in animals with higher plasma insulin (>5 muIU/ml) and leptin (>20 ng/ml), sugg

142 Fasting plasma insulin had increased by week 6 (150% of week 0)

143 VNS for 12 weeks significantly decreased plasma insulin, HOMA index, total cholesterol, triglycer

144 amed CLS+ obese individuals displayed higher plasma insulin, homeostasis model assessment, triglyceri

145 diabetes characterized by a 50% decrease in plasma insulin, hyperglycemia, and insulin resistance (I

146 The Bayesian network identified plasma insulin, IL-6, leukocyte number, and adipose tiss

147 TG mice displayed increased plasma insulin, improved glucose tolerance, and enhanced

148 ma glucagon and glucose levels and decreases plasma insulin in fasted rats.

149 1 decreased glucose tolerance and suppressed plasma insulin in lean and DIO mice, despite FFA2(-/-) m

150 Interestingly, the reduced plasma insulin in M4K4 iKO mice exposed to chronic (16 w

151 icantly lowered plasma glucose and increased plasma insulin in mice.

152 icantly lowered plasma glucose and increased plasma insulin in normal and obese diabetic (ob/ob) mice

153 correlation between plasma 26RFa levels and plasma insulin in patients with diabetes.

154 mmon meal on postprandial plasma glucose and plasma insulin in patients with type 2 diabetes (T2D).A

155 -cells leads to an age-dependent decrease in plasma insulin in the fed state and in response to a glu

156 nd the hepatic portal-arterial difference in plasma insulin increased from 60 +/- 18 and 78 +/- 24 to

157 to investigate how physiological changes in plasma insulin influence EGP in healthy subjects.

158 After the control period, plasma insulin infusion 1) was discontinued, creating in

159 Here we show that in normal mice, plasma insulin inhibits the forkhead transcription facto

160 At baseline, cluster C had the highest plasma insulin, interleukin (IL)-6, adipose tissue infla

161 se at a reasonably low level and ensure that plasma insulin is maintained at levels high enough to pr

162 Plasma insulin is pulsatile and reflects oscillatory ins

163 Plasma insulin kinetics were determined for each dog, an

164 examined relationships between ventilation, plasma insulin, leptin, ketones, and blood glucose level

165 Increased plasma insulin level and mitochondrial dysfunction are f

166 llele associated with an increase in fasting plasma insulin level and risk of type 2 diabetes.

167 The arterial plasma insulin level increased to 15 +/- 2 microU/ml and

168 At the time when the normalization of the plasma insulin level was expected, all hamsters were tre

169 evel coupled with slight increase in fasting plasma insulin level was observed.

170 insulin deficiency or a fourfold rise in the plasma insulin level were assessed during a 5-h experime

171 ile 1 after adjustment for age, sex, fasting plasma insulin level, 2-hour plasma glucose level, body

172 utation than in controls (e.g., mean fasting plasma insulin level, 29 pmol per liter [range, 9 to 99]

173 The male AT(2)KO on HFD displayed lower plasma insulin level, less impaired glucose tolerance (G

174 nt for insulin resistance (HOMA-IR), fasting plasma insulin level, Matsuda index, and area under the

175 were obtained for predicting future fasting plasma insulin level, Matsuda index, and AUC of insulin.

176 ctly improve insulin resistance and decrease plasma insulin levels (a risk factor for coronary artery

177 In individuals with higher baseline plasma insulin levels (above median >12 muIU/ml; n = 99)

178 61; 95% CI, 0.16 to 1.05; P = .007), fasting plasma insulin levels (Hedges g = 0.41; 95% CI, 0.09 to

179 ) were significantly associated with fasting plasma insulin levels (P </= 0.00295).

180 Arterial plasma insulin levels (pmol/l) and the hepatic portal-ar

181 Leptin decreased plasma insulin levels abruptly, and an approximately two

182 esistant, as demonstrated by markedly higher plasma insulin levels and a blunted response to insulin;

183 Fetal plasma insulin levels and body weight were also unaffect

184 on, in association with an acute decrease in plasma insulin levels and decreased sterol regulator ele

185 00070 exhibited a significant improvement in plasma insulin levels and glucose tolerance as well as a

186 to glucose resulted in smaller increases in plasma insulin levels and greater brain reactivity to fo

187 14605/rs1078199 were associated with fasting plasma insulin levels and HOMA-IR.

188 Ogg1(-/-) animals also have higher plasma insulin levels and impaired glucose tolerance upo

189 intimately linked to its potential to lower plasma insulin levels and improve glycemic control throu

190 mice are glucose intolerant, despite normal plasma insulin levels and insulin sensitivity.

191 umulin R; n = 6) using an algorithm to match plasma insulin levels and kinetics for both groups.

192 The arterial plasma insulin levels and the hepatic portal-arterial di

193 Arterial plasma insulin levels and the hepatic portal-arterial di

194 gh the associations with type 2 diabetes and plasma insulin levels are marginal and their functional

195 However, during high-fat feeding, their plasma insulin levels are mildly elevated in association

196 hat show significant evidence for linkage to plasma insulin levels as a quantitative trait.

197 fferences were observed in blood glucose and plasma insulin levels at 1 week of age.

198 ciation between gestational age and elevated plasma insulin levels at birth and in early childhood.

199 wever, there was an increase in steady-state plasma insulin levels at weeks 6 and 12, indicating a mo

200 re was a gradual and progressive decrease in plasma insulin levels by 52% with 30 ng (P<0.005) and by

201 Insufficient plasma insulin levels caused by deficits in both pancrea

202 ly, and an approximately twofold decrease in plasma insulin levels compared with saline control was s

203 Increasing plasma insulin levels decreased myocardial fatty acid es

204 ients, insulin sensitivity improved, fasting plasma insulin levels decreased, and myocardial blood fl

205 The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect o

206 n, GX KO mice showed significantly increased plasma insulin levels following glucose challenge and we

207 This study establishes that low plasma insulin levels have a detrimental effect on two m

208 ets, and caused a dose-dependent increase in plasma insulin levels in fasted rats, with a half-maxima

209 hich improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subject

210 ed in these mice, associated with attenuated plasma insulin levels in response to glucose challenge.

211 Clinical studies suggest that plasma insulin levels may predict the extent of cardiova

212 These parameters, together with 24-h plasma insulin levels measured during ad libitum feeding

213 In healthy individuals, plasma insulin levels oscillate in both fasting and fed

214 Fasting plasma insulin levels rose 2.5-fold from 6 to 14 mo of a

215 LAD-fed mice showed lower fasting plasma insulin levels throughout the study (P = 0.01).

216 Moreover, a dose-dependent decrease in plasma insulin levels was noted (r = -0.731, P < 0.01).

217 In early childhood, random plasma insulin levels were 1.12-fold (95% CI, 0.99-1.25)

218 eletion prevented fasting hyperglycemia, and plasma insulin levels were also dramatically improved.

219 een apoA-II transgenic and control mice, but plasma insulin levels were elevated approximately twofol

220 nsequence, under fasting conditions in which plasma insulin levels were identical, blood glucose leve

221 Random plasma insulin levels were measured at 2 time points: at

222 issue macrophage content, were reversed when plasma insulin levels were normalized by insulin supplem

223 tration of WAY200070 leads to an increase in plasma insulin levels with a concomitant improved respon

224 d neonatal diabetes (associated with reduced plasma insulin levels) and died of hyperglycemia 3 days

225 Despite higher plasma insulin levels, BKS-db mice exhibit lower lipogen

226 play variable phenotypes relating to fasting plasma insulin levels, glucose tolerance, and insulin se

227 creatic beta cell mass, but markedly reduced plasma insulin levels, in both fed and fasted conditions

228 fter an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and HbA1c lev

229 fter an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and hemoglobi

230 The contribution of plasma insulin levels, lipoproteins, markers of oxidized

231 educed levels of plasma glucose and elevated plasma insulin levels, similar to children with SCHAD de

232 lucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound impr

233 mans and animal models, an acute increase in plasma insulin levels, typically following meals, leads

234 enhanced insulin sensitivity, with decreased plasma insulin levels.

235 plasma adrenaline and cortisol, and reduced plasma insulin levels.

236 nsulin sensitivity with significantly higher plasma insulin levels.

237 ody mass index, smoking, and blood lipid and plasma insulin levels.

238 s having only basal and nonglucose-regulated plasma insulin levels.

239 a third locus that strongly links to fasting plasma insulin levels.

240 l levels impair insulin secretion and reduce plasma insulin levels.

241 lar weight adiponectin and decreased fasting plasma insulin levels.

242 1 did not enhance insulin action or increase plasma insulin levels.

243 erse insulin resistance but improved fasting plasma insulin levels.

244 insulin storage in beta-cells, and increased plasma insulin levels.

245 -dependent increase in insulin secretion and plasma insulin levels.

246 tervention and stratified analyses by median plasma insulin levels.

247 or impairs glucose disposal due to decreased plasma insulin levels.

248 Plasma insulin-like growth factor (IGF)-I and colonic IG

249 rmone (GH) is seen with 40-50% reductions in plasma insulin-like growth factor (IGF)-I.

250 Plasma insulin-like growth factor I (IGF-I) and the conc

251 or significant differences by supplement in plasma insulin-like growth factor-binding protein 3 (44

252 rs2854746 was significantly associated with plasma insulin-like growth factor-binding protein-3.

253 like growth factor-I mRNA but did not affect plasma insulin-like growth factor-I.

254 fied as being normoinsulinemic (NI) (fasting plasma insulin <11.2 mU/L, n = 18) or hyperinsulinemic (

255 (insulin-stimulated glucose uptake per unit plasma insulin [M/I]) independent of other mechanisms.

256 Plasma insulin measurements from mice, rats, dogs, and h

257 T(2)KO mice on HFD showed elevated levels of plasma insulin, more impaired GT, lower plasma T3 and hi

258 The increased plasma insulin observed in Galphaz-null mice is most lik

259 ons are likely responsible for the pulses of plasma insulin observed in vivo.

260 infusion nor exercise significantly affected plasma insulin or free fatty acid (FFA) concentrations.

261 Ghrelin infusion did not alter fasting plasma insulin or glucose, but compared with saline, the

262 aseline serum resistin levels and changes in plasma insulin or HGO (r = 0.26 and 0.23; both P > 0.1).

263 ression was not associated with decreases in plasma insulin or leptin levels.

264 ether loss of gap-junction coupling disrupts plasma insulin oscillations and whether this impacts glu

265 Plasma insulin oscillations are known to have physiologi

266 These pulses are thought to lead to plasma insulin oscillations, which are putatively more e

267 as also significantly associated with higher plasma insulin (P = 0.019), increased HOMA insulin resis

268 nd the hepatic portal-arterial difference in plasma insulin (pmol/l) decreased (P < 0.01) from 78 +/-

269 lenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF

270 Good agreement between modeled and measured plasma insulin profiles was observed (mean normalized ro

271 ne correlated with the reductions in fasting plasma insulin (r = 0.60, P < 0.05), nonesterified fatty

272 Baseline plasma insulin ranged from 76 to 695 pmol/L (271 +/- 188

273 alculation of CNS insulin uptake: the CSF-to-plasma insulin ratio during the insulin infusion.

274 Aging (15-17 m) (F) not (M), expressed low plasma insulin, reduced brain IRS-2, pAkt, and pGSK-3bet

275 ssion analysis showed that SSPG and day-long plasma insulin response were the only significant predic

276 Plasma insulin responses to meal challenges were blunted

277 +/- 0.2 to 7.3 +/- 0.4 mmol/l, and arterial plasma insulin rose from 42 +/- 6 to 258 +/- 66 pmol/l a

278 em microinjection of APDC or L-AP4 decreased plasma insulin secretion, whereas only APDC microinjecti

279 c volunteers by measuring their steady-state plasma insulin (SSPI) and glucose (SSPG) concentrations

280 t data indicate that sustained elevations in plasma insulin suppress the mRNA for IRS-2, a component

281 nificantly altered, there was a tendency for plasma insulin to be greater (hepatic levels were 73 +/-

282 (calculated as the ratio of the increment in plasma insulin to glucose [OGTT/IR (DeltaI/DeltaG / IR)]

283 On day 7, plasma insulin to glucose ratio tended to be lower in th

284 In contrast, elevation of plasma insulin to physiological postprandial levels fail

285 The response of plasma insulin to starvation and re-feeding was normal i

286 Plasma insulin, triacylglycerol, and RLP-cholesterol con

287 Plasma insulin values were also not different between th

288 The hepatic portal-arterial difference in plasma insulin was again eliminated.

289 During the first 20 min of the FSIGT, plasma insulin was approximately twice as high in AAs as

290 Plasma insulin was elevated, which reflected insulin res

291 The hepatic portal-arterial difference in plasma insulin was eliminated, indicating a complete inh

292 r, which suggests decreased ureagenesis, and plasma insulin was higher with the GMP diet than with th

293 In LAR-transgenic mice, fasting plasma insulin was increased 2.5-fold compared with wild

294 Plasma insulin was measured via ELISA and indices of ana

295 Plasma insulin was significantly elevated within 30 min

296 Fasting plasma insulin was used as a surrogate measure of insuli

297 Basal hepatic IR index (EGP x fasting plasma insulin) was increased in T2DM (NGT, 816 +/- 54;

298 weight, body composition, plasma glucose and plasma insulin were monitored.

299 sis is acutely sensitive to small changes in plasma insulin, whereas gluconeogenic flux is not.

300 travenous insulin infusion rapidly increases plasma insulin, yet glucose disposal occurs at a much sl